News & Events
The role deep grey matter in the brain plays in MS
Deep grey matter is profoundly involved in the disease progression of MS patients
The role of iron and brain damage in MS
The presence of iron could help us understand the MS inflammation process
Progressive MS and disease-modifying drugs
Patients with secondary progressive MS who have ongoing relapses may benefit from continuing immunomodulatory therapies after onset…
Improving diagnosis of MS
Over 35 per cent of patients with clinically isolated syndrome were diagnosed earlier when applying the 2010…
Disappointing results from fingolimod trial in primary progressive MS
The results suggest that primary progressive and relapsing forms of MS have different underlying mechanisms
Positive outcomes in changing from interferon to glatiramer acetate
Switching patients with relapsing-remitting MS from interferon to glatiramer acetateis associated with positive treatment outcomes
No target met unless met for all
MS International Federation calls on the UN to ensure new global goals benefit all - including people…
Six months to World MS Day
The theme for 2015 will be access, and the campaign will celebrate breaking down barriers to living…
Progressive MS Alliance expands
The Alliance has been joined by four MS International Federation member organisations
Universal access declaration reaches 88,000 signatures
The MS International Federation encourages everyone affected by MS to sign the declaration
Underweight women on fingolimod at higher risk of lymphopenia
Underweight women and patients with low baseline lymphocyte counts should be monitored more closely
Using spectroscopy to recognize secondary-progressive MS patients
A new way to predict the transition from relapsing-remitting to secondary-progressive MS